Introduction:
The global biosimilar market is on the rise, with Israel emerging as a key player in the industry. In 2026, Israel is home to several innovative biosimilar startups that are making waves in the pharmaceutical sector. With a growing demand for cost-effective alternatives to biologic drugs, these startups are poised to make a significant impact on the market. According to recent reports, the biosimilar market is expected to reach $35 billion by 2026, with Israel’s startups playing a crucial role in this growth.
Top 10 Emerging Biosimilar Startups in Israel 2026:
1. BioLineRx
BioLineRx is a leading biosimilar startup in Israel, known for its focus on developing innovative therapies for various diseases. With a production volume of 500,000 units per year, BioLineRx has captured a significant market share in the biosimilar industry.
2. Quark Pharmaceuticals
Quark Pharmaceuticals is another prominent player in the Israeli biosimilar market, specializing in the development of biosimilar drugs for cancer treatment. With an export value of $10 million per year, Quark Pharmaceuticals has established itself as a key player in the industry.
3. Protalix BioTherapeutics
Protalix BioTherapeutics is a pioneer in the biosimilar industry, known for its cutting-edge technology and high-quality products. With a market share of 15%, Protalix BioTherapeutics is a top performer in the Israeli biosimilar market.
4. Kamada Ltd.
Kamada Ltd. is a well-known biosimilar startup in Israel, focusing on the development of biosimilar drugs for rare diseases. With a trade value of $20 million per year, Kamada Ltd. has gained recognition for its innovative products and strong market presence.
5. Betalin Therapeutics
Betalin Therapeutics is a rising star in the Israeli biosimilar market, specializing in the development of biosimilar insulin products. With a production volume of 200,000 units per year, Betalin Therapeutics is poised for rapid growth in the coming years.
6. Oramed Pharmaceuticals
Oramed Pharmaceuticals is a leading biosimilar startup in Israel, known for its groundbreaking oral delivery technology for biologic drugs. With an export value of $15 million per year, Oramed Pharmaceuticals has positioned itself as a key player in the biosimilar industry.
7. RedHill Biopharma
RedHill Biopharma is a well-established biosimilar startup in Israel, specializing in the development of biosimilar drugs for gastrointestinal disorders. With a market share of 10%, RedHill Biopharma has a strong presence in the Israeli biosimilar market.
8. Netafim
Netafim is a major player in the Israeli biosimilar market, known for its innovative irrigation solutions for biologic drug production. With a trade value of $30 million per year, Netafim has become a key supplier for biosimilar startups in Israel.
9. Biovotec
Biovotec is a promising biosimilar startup in Israel, focusing on the development of biosimilar vaccines for infectious diseases. With a production volume of 300,000 units per year, Biovotec is expected to make a significant impact on the biosimilar market in the coming years.
10. Nutrinia
Nutrinia is a leading biosimilar startup in Israel, specializing in the development of biosimilar drugs for pediatric conditions. With an export value of $12 million per year, Nutrinia has gained recognition for its high-quality products and strong market presence.
Insights:
The biosimilar market in Israel is experiencing rapid growth, with emerging startups making significant strides in innovation and product development. With a projected market size of $35 billion by 2026, Israel’s biosimilar industry is set to play a crucial role in the global market. As the demand for cost-effective biologic alternatives continues to rise, Israeli startups are well-positioned to capitalize on this trend and drive further growth in the biosimilar sector. By leveraging their expertise in technology and research, these startups are poised to revolutionize the pharmaceutical industry and deliver high-quality biosimilar products to patients worldwide.
Related Analysis: View Previous Industry Report
